AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23489780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous drainage and alcohol sclerotherapy with single-session multiple injections
Number of subjects: 144
Study 23489780 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided simple percutaneous drainage
Number of subjects: 144
Study 21683382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical voiding reeducation program (voiding school)
Number of subjects: 38
Study 21683382 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 38
Study 19663091 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle plus rehabilitation training
Number of subjects: 92
Study 19663091 — intervention group
Group type: COMPARATOR
Intervention: Medication plus rehabilitation training
Number of subjects: 92
Study 17014816 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women undergoing stress urinary incontinence surgery
Number of subjects: 250
Study 17014816 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 250
Study 17014816 — intervention group
Group type: COMPARATOR
Intervention: Obese women and nonobese women
Number of subjects: 250
Study 15238420 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative radiochemotherapy followed by autologous stem cell transplantation (ASCT)
Number of subjects: 307
Study 15238420 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alpha (IFN‐alpha) maintenance therapy
Number of subjects: 307
Study 11740135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 97
Study 11740135 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate 25-50 mg once daily
Number of subjects: 97
Study 9228489 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section
Number of subjects: 165
Study 9228489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extraction
Number of subjects: 165
Study 9228489 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal neurological examination
Number of subjects: 165
Study 9228489 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimbabwean population
Number of subjects: 165
Study 28712090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 232
Study 29734347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 37
Study 29734347 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 37
Study 29734347 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 37
Study 29734347 — intervention group
Group type: EXPERIMENTAL
Intervention: All tDCS conditions
Number of subjects: 37
Study 26032407 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle stretching (3 times 30 seconds, 7 days a week for 4 weeks)
Number of subjects: 40
Study 26032407 — intervention group
Group type: COMPARATOR
Intervention: No stretching (control group)
Number of subjects: 40
Study 24990788 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine (4%) + epinephrine (1:200 000) + clonidine (1:100 000)
Number of subjects: 0
Study 24990788 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine (4%) + epinephrine (1:400 000) + clonidine (1:100 000)
Number of subjects: 0
Study 24990788 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine (4%) + clonidine (1:100 000)
Number of subjects: 0
Study 24990788 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine (4%) + epinephrine (1:200 000)
Number of subjects: 0
Study 22985218 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (1 hour per session, twice a week for 12 weeks)
Number of subjects: 59
Study 22985218 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 59
Study 20451040 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (32-8 mg once daily for 20 days)
Number of subjects: 47
Study 20451040 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 20 days)
Number of subjects: 47
Study 20451040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19126019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of 2025 U Botulinum toxin type A (BTA)
Number of subjects: 9
Study 19126019 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 9
Study 16787142 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using LHRH agonist or orchiectomy plus dexamethasone and somatostatin analogue
Number of subjects: 0
Study 10385667 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 million units (MU) of IFN‐alpha‐2a, Roferon‐A, thrice weekly for 6 months
Number of subjects: 57
Study 10385667 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 57
Study 8800895 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 79
Study 8800895 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 79
Study 8800895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion
Number of subjects: 79
Study 8800895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 79
Study 1503142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine
Number of subjects: 12
Study 1503142 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular atropine
Number of subjects: 12
Study 6401946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intraoperative antibiotic irrigation
Number of subjects: 200
Study 31103811 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap fixation using sutures (FF-S)
Number of subjects: 187
Study 31103811 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap fixation using adhesive tissue glue (FF-G)
Number of subjects: 187
Study 31103811 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure without flap fixation (CON)
Number of subjects: 187
Study 29508899 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg/m2 per cycle for ≤6 cycles)
Number of subjects: 326
Study 29508899 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC: fludarabine/cytarabine [ara‐C]/granulocyte colony‐stimulating factor, or ara‐C plus mitoxantrone, or high‐dose ara‐C for ≤4 cycles)
Number of subjects: 326
Study 24179073 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD shocks
Number of subjects: 1790
Study 24179073 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate ICD shocks (after adjusting for echocardiographic remodelling)
Number of subjects: 1790
Study 24179073 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate anti-tachycardia pacing (ATP) only
Number of subjects: 1790
Study 24179073 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate shocks
Number of subjects: 1790
Study 24179073 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ATP
Number of subjects: 1790
Study 22789611 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 0
Study 22789611 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir and zidovudine/lamivudine (Kaletra/Combivir)
Number of subjects: 0
Study 19280799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring (HS) autograft
Number of subjects: 20
Study 19280799 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BTB) autograft
Number of subjects: 20
Study 19280799 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog scales and knee girth measurements
Number of subjects: 20
Study 17898949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongluo yangyin recipe (TLYYR) 200 mL in water decoction daily for 28 days
Number of subjects: 99
Study 17898949 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B1 100 mg and Vitamin B12 250 microg administered daily via intramuscular injection for 28 days
Number of subjects: 99
Study 15172082 — intervention group
Group type: EXPERIMENTAL
Intervention: S21400 300 microg per day
Number of subjects: 361
Study 15172082 — intervention group
Group type: COMPARATOR
Intervention: Patch E2 (delivering 50 microg per day, two patches per week)
Number of subjects: 361
Study 12224199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs)
Number of subjects: 0
Study 12224199 — intervention group
Group type: COMPARATOR
Intervention: Physicians (MDs)
Number of subjects: 0
Study 12224199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs) and Physicians (MDs)
Number of subjects: 0
Study 9704387 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits
Number of subjects: 20
Study 9704387 — intervention group
Group type: COMPARATOR
Intervention: Noncoated circuits
Number of subjects: 20
Study 7863255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at night
Number of subjects: 28
Study 7863255 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 28
Study 7863255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 28
Study 2815851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg digoxin tablets
Number of subjects: 17
Study 2815851 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg digoxin capsules
Number of subjects: 17
Study 2815851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative urinary excretion of digoxin
Number of subjects: 17
Study 1097099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (40-75 mg/m intravenously every 3 weeks)
Number of subjects: 69
Study 1097099 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 69
Study 1097099 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 69
Study 31834217 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic treatment using a set of 4 devices
Number of subjects: 247
Study 31834217 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 247
Study 30956253 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) approach
Number of subjects: 2500
Study 27871056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine
Number of subjects: 25
Study 27871056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine (for patients with high S2 accommodation)
Number of subjects: 25
Study 27871056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine (for patients with low S2 accommodation)
Number of subjects: 25
Study 27871056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25678773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate (HA) and 0.5% levofloxacin
Number of subjects: 30
Study 25678773 — intervention group
Group type: COMPARATOR
Intervention: Topical recombinant bovine basic fibroblast growth factor (rb‐bFGF) and 0.5% levofloxacin
Number of subjects: 30
Study 22998746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day patching for 8 hr or more
Number of subjects: 40
Study 22998746 — intervention group
Group type: COMPARATOR
Intervention: Patching daily 6 days weekly for 8 hr or more
Number of subjects: 40
Study 22998746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 22998746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day patching
Number of subjects: 40
Study 22998746 — intervention group
Group type: COMPARATOR
Intervention: Patching daily 6 days weekly
Number of subjects: 40
Study 22998746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21774699 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal (TEP) procedure
Number of subjects: 166
Study 21774699 — intervention group
Group type: COMPARATOR
Intervention: Darn plication
Number of subjects: 166
Study 18941892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 18941892 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 18941892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor aromatase expression
Number of subjects: 0
Study 16968595 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination
Number of subjects: 40
Study 12766664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs) after tonsillectomy
Number of subjects: 7
Study 12766664 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7
Study 10920582 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP65 and HSP72/73 expression in atopic dermatitis
Number of subjects: 21
Study 10920582 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP65 and HSP72/73 expression in infiltrating cells
Number of subjects: 21
Study 10920582 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP27 expression
Number of subjects: 21
Study 10920582 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of atopic dermatitis
Number of subjects: 21
Study 8615363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 25000
Study 8615363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25000
Study 1573126 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT2 receptor antagonist, ritanserin
Number of subjects: 24
Study 1573126 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy matched controls)
Number of subjects: 24
Study 4014253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric extension set for drug delivery
Number of subjects: 12
Study 4014253 — intervention group
Group type: COMPARATOR
Intervention: Syringe pump
Number of subjects: 12
Study 4014253 — intervention group
Group type: COMPARATOR
Intervention: IV push
Number of subjects: 12
Study 31662003 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional arterial infusion (RAI) combined with early enteral nutrition (EEN)
Number of subjects: 100
Study 31662003 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 100
Study 29534597 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency, smaller reward lottery
Number of subjects: 209
Study 29534597 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackpot lottery
Number of subjects: 209
Study 29534597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lottery
Number of subjects: 209
Study 29534597 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 209
Study 28304237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige LP cervical disc arthroplasty
Number of subjects: 397
Study 28304237 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 397
Study 25069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO), administered subcutaneously at a daily dose of 15,000 U from the first day after transplantation.
Number of subjects: 120
Study 25069650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhTPO treatment).
Number of subjects: 120
Study 25069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO).
Number of subjects: 120
Study 25069650 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO) and control group (no rhTPO treatment).
Number of subjects: 120
Study 23212147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily (M group)
Number of subjects: 97
Study 23212147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily (S group)
Number of subjects: 97
Study 23212147 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinic therapy (Control group)
Number of subjects: 97
Study 23212147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (both groups)
Number of subjects: 97
Study 21252846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic CVD diamond tip
Number of subjects: 40
Study 21252846 — intervention group
Group type: COMPARATOR
Intervention: High-speed diamond bur
Number of subjects: 40
Study 18468195 — intervention group
Group type: COMPARATOR
Intervention: Mitral stenosis and chronic AF patients
Number of subjects: 57
Study 18468195 — intervention group
Group type: COMPARATOR
Intervention: Patients with chronic AF
Number of subjects: 57
Study 17139643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptomatic State (PASS) for global pain (VAS)
Number of subjects: 330
Study 17139643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptomatic State (PASS) for nocturnal pain (VAS)
Number of subjects: 330
Study 17139643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptomatic State (PASS) for patient's global assessment of disease activity (VAS)
Number of subjects: 330
Study 17139643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptomatic State (PASS) for Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 330
Study 17139643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptomatic State (PASS) for Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Number of subjects: 330
Study 12784978 — intervention group
Group type: EXPERIMENTAL
Intervention: Quixil fibrin glue (0.5 mL to each tonsillar fossa and 0.5 mL to the nasopharynx in adenoidectomy)
Number of subjects: 179
Study 12784978 — intervention group
Group type: COMPARATOR
Intervention: Bipolar or needle point electrocautery
Number of subjects: 179
Study 11014398 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction during physical therapy
Number of subjects: 12
Study 11014398 — intervention group
Group type: COMPARATOR
Intervention: No distraction during physical therapy
Number of subjects: 12
Study 9308132 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects meta-analysis across cluster pairs
Number of subjects: 0
Study 9308132 — intervention group
Group type: COMPARATOR
Intervention: Previously published methods for cluster randomized trials
Number of subjects: 0
Study 8345812 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol diet (800 mg/d)
Number of subjects: 13
Study 8345812 — intervention group
Group type: COMPARATOR
Intervention: Low cholesterol diet (250 mg/d)
Number of subjects: 13
Study 2953318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2)
Number of subjects: 0
Study 2953318 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (Rx-1)
Number of subjects: 0
Study 2953318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3)
Number of subjects: 0
Study 31563135 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) performed by clamping 60 seconds after birth
Number of subjects: 0
Study 31563135 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 0
Study 29436756 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (increased to 150 mg every 2 weeks at week 12 if necessary)
Number of subjects: 413
Study 29436756 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 413
Study 29436756 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 413
Study 27225610 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral analgesia (PV group)
Number of subjects: 35
Study 27225610 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (ED group)
Number of subjects: 35
Study 25040793 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score 29-27
Number of subjects: 17538
Study 25040793 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score 26-24
Number of subjects: 17538
Study 25040793 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE score <24
Number of subjects: 17538
Study 25040793 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous MVC within 2 years
Number of subjects: 17538
Study 25040793 — intervention group
Group type: EXPERIMENTAL
Intervention: Other clinical factors (depression, falls, sleep apnea, lower systolic blood pressure)
Number of subjects: 17538
Study 23002085 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication use at previous visit
Number of subjects: 1442
Study 23002085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative antidepressant medication use as percent of visits
Number of subjects: 1442
Study 23002085 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms (BDI score ≥11)
Number of subjects: 1442
Study 21644104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tramadol
Number of subjects: 24
Study 21644104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tramadol
Number of subjects: 24
Study 21644104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% tramadol
Number of subjects: 24
Study 21644104 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24
Study 19463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 60
Study 19463374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19463374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg daily maintenance dose
Number of subjects: 60
Study 19463374 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily maintenance dose
Number of subjects: 60
Study 16931510 — intervention group
Group type: EXPERIMENTAL
Intervention: 23Na magnetic resonance (MR) sequence with ultra‐short echo times
Number of subjects: 23
Study 16931510 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 16931510 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements on native muscle fibers
Number of subjects: 23
Study 16931510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined in vivo and in vitro approach
Number of subjects: 23
Study 12924542 — intervention group
Group type: COMPARATOR
Intervention: SQV 1400 mg without itraconazole
Number of subjects: 17
Study 12924542 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV 1200 mg with itraconazole
Number of subjects: 17